Tranexamic Acid for Melasma: Research, Results and Reality

Tranexamic acid doesn't follow the usual playbook for brightening ingredients.

It wasn't discovered in a dermatology lab. It wasn't designed for skin at all. It was originally developed as a haemostatic agent — a drug used to control bleeding during surgery. Dermatologists noticed it as a skin treatment almost by accident, when patients taking it orally for other reasons reported unexpected improvements in their melasma.

That accidental discovery led to a body of clinical research that is, frankly, stronger than what most skincare ingredients will ever have. And yet tranexamic acid is absent from most over-the-counter brightening creams. There's a specific reason for that — and understanding it helps you understand both the ingredient's real power and its practical limitations.

Does Tranexamic Acid Work for Melasma?

Yes — tranexamic acid has some of the strongest clinical evidence of any ingredient specifically for melasma. A retrospective study published in the Journal of the American Academy of Dermatology found 89.7% of patients documented improvement, typically after two months. A randomised trial found oral tranexamic acid reduced MASI scores by 58.86% and topical by 50.88% over 12 weeks. It works through a mechanism completely different from tyrosinase inhibitors — blocking the plasminogen/plasmin pathway that stimulates melanocytes — which is why it's particularly effective for the inflammatory and hormonal components of melasma that other actives don't address.

How Tranexamic Acid Was Discovered for Melasma

In the 1970s and 1980s, tranexamic acid was used as an antifibrinolytic agent — a medical drug that prevents blood clots from breaking down, used during surgeries and to manage heavy bleeding. Clinicians began noticing something unexpected: patients taking it orally for these purposes were reporting lightening of their melasma as a side effect.

This observation kicked off decades of dermatological research — first on oral tranexamic acid, then on topical formulations, and more recently on injected and iontophoresis-delivered forms. The result is a breadth and depth of clinical evidence for melasma specifically that's rare for a cosmetic ingredient.

What Tranexamic Acid Actually Does — The 

Most brightening ingredients target melanin production by inhibiting tyrosinase — the enzyme that triggers the melanin synthesis pathway. Tranexamic acid works through a completely different route, which is a large part of why it works where other ingredients fall short for melasma.

Data shows tranexamic acid slows melanin synthesis by inhibiting the plasminogen/plasmin pathway, blocking interactions between melanocytes and keratinocytes. In plain terms: UV exposure and inflammation activate plasminogen in keratinocytes (surface skin cells), which then stimulates melanocytes to produce more melanin. Tranexamic acid interrupts this activation step — addressing the communication pathway between surface skin cells and pigment-producing cells before melanin production even begins.

The result is that tranexamic acid addresses something tyrosinase inhibitors don't cover. You can inhibit tyrosinase all you want, but if the activation signal from keratinocytes to melanocytes remains in place — as it does in hormonally and UV-driven melasma — the tyrosinase just gets re-stimulated continuously. Tranexamic acid cuts that signal.

Using either oral or topical tranexamic acid can decrease melasma-associated skin pigmentation and reverse any melasma-related dermal changes, including reduced redness and a decreased number of vessels. That vascular effect — reducing the number of blood vessels visible through the skin — is unique among common brightening ingredients and directly relevant for the redness that often accompanies melasma patches.

The Clinical Evidence — What Studies Found

Oral Tranexamic Acid: 89.7% of Patients Improved

In a retrospective analysis published in a 2016 Journal of the American Academy of Dermatology issue — selected as a "game changer" study in 2018 — nearly 90 percent (89.7%) of patients documented melasma improvement. The study included melasma patients treated over four years, with improvement occurring typically after two months of twice-daily 250 mg doses.

This 89.7% response rate across a real-world clinical population — not a curated trial group — is a striking finding for a condition as notoriously resistant to treatment as melasma.

Head-to-Head: Oral vs Topical Over 12 Weeks

A randomised clinical trial enrolled 50 female melasma patients, equally divided between oral TXA (250 mg twice daily) and topical TXA (5% cream twice daily) for 12 weeks. After 12 weeks, both groups demonstrated significant reductions in MASI scores — oral group: 58.86%; topical group: 50.88% — though the difference between the two groups was not statistically significant.

A 50.88% reduction in melasma severity from topical application alone — measured using the clinical Melasma Area and Severity Index — is a substantial result. And the fact that topical came close to oral is significant for anyone looking for an OTC-accessible approach.

Oral TXA Also Reduces Inflammation — Not Just Pigmentation

A retrospective study of 80 melasma patients treated with oral TXA (500 mg/day) for 3 months found a 65.1% reduction in MASI scores (from 12.9 to 4.5, p < 0.001). Beyond pigmentation, inflammatory markers — monocyte, neutrophil, MHR, MLR, and NLR levels — significantly decreased, suggesting oral TXA not only improved melasma severity but also modulated systemic inflammation.

This anti-inflammatory effect matters for melasma specifically. Melasma is not purely a melanin overproduction disorder — it has a vascular and inflammatory component that most topical brightening actives don't address. Tranexamic acid hitting both makes it uniquely suited to the condition.

Oral vs Topical: Efficacy Comparison

A prospective, randomised study of 40 melasma patients compared oral tranexamic acid (250 mg twice daily) against topical 3% tranexamic acid over 8 weeks. Mean percentage reduction in MASI scores was 52.1% in the oral group versus 31.9% in the topical group, with 75% of oral and 70% of topical group patients achieving fair improvement — showing no significant difference between the two groups at final assessment.

Why Tranexamic Acid Isn't in Most Over-the-Counter Creams

This is the part most ingredient articles skip — and it's the most practically useful thing to understand.

Stability in formulation. Tranexamic acid is water-soluble and relatively stable, but formulating it at effective concentrations (typically 2–5% topically) while maintaining pH stability and compatibility with other actives is technically more demanding than most brightening ingredients. Many OTC formulations contain it at concentrations too low to deliver the results seen in clinical trials.

Effective concentration requires care. The clinical studies showing meaningful results used 3–5% topical concentration. At lower concentrations, the plasminogen/plasmin pathway inhibition may not reach the threshold needed for measurable effect. A product that lists tranexamic acid without disclosing concentration — or that contains it as a trace ingredient — is unlikely to replicate clinical trial results.

Cost. Tranexamic acid at effective concentrations costs more to include than many standard brightening actives. For products competing primarily on price in a crowded market, this makes it less appealing to formulators.

Oral form has the strongest data — but requires a prescription. The most dramatic results in clinical research come from oral tranexamic acid, which delivers systemic anti-inflammatory and anti-melanogenic action that topical simply can't replicate. Oral tranexamic acid for melasma is available in India but requires dermatologist prescription — it's not an ingredient you can buy in a cream.

Where Tranexamic Acid Fits in a Melasma Routine

Tranexamic acid works on a mechanism that's genuinely different from tyrosinase inhibitors — which means it's most powerful as a complement to, not a replacement for, ingredients like Alpha Arbutin, TYROSTAT-09, and Niacinamide.

A well-designed melasma routine covers:

• Melanin production (Step 1) — tyrosinase inhibitors: Alpha Arbutin, TYROSTAT-09
• Melanin transfer (Step 2) — Niacinamide
• UV re-triggering (Step 3) — stable Vitamin C, daily SPF
• Keratinocyte-melanocyte signalling — Tranexamic Acid (where available)

Ocevia Skin Brightening Cream covers Steps 1–3 with TYROSTAT-09 (1%), Alpha Arbutin (1%), Niacinamide (3%), and Ethyl Ascorbic Acid (0.5%). For melasma patients specifically, adding tranexamic acid — either as a topical serum (look for 2–3%) or under dermatologist guidance as oral — builds on this base by addressing the keratinocyte activation pathway that tyrosinase inhibitors alone don't cover.

For stubborn melasma that hasn't responded fully to a standard brightening routine, this is where a dermatologist consultation specifically for tranexamic acid (oral or topical) adds a clinically distinct layer of treatment.

Myth vs Fact

Myth: Tranexamic acid is a new, unproven brightening ingredient. Fact: Tranexamic acid's dermatological use dates to observations made in the 1970s and 1980s. The 2016 retrospective study on oral tranexamic acid was selected as a "game changer" study by the Journal of the American Academy of Dermatology in 2018. Its mechanism has been studied across oral, topical, intradermal, and iontophoresis delivery methods — few OTC ingredients have broader clinical investigation for melasma specifically.

Myth: Topical tranexamic acid is significantly weaker than oral and not worth using. Fact: A head-to-head randomised trial found topical tranexamic acid (5%) achieved 50.88% MASI reduction in 12 weeks versus 58.86% for oral — not statistically significantly different. For people unable or unwilling to take oral medication, a well-formulated topical at 3–5% is a clinically meaningful option.

Myth: If you're already using Alpha Arbutin and Niacinamide, tranexamic acid is redundant. Fact: Tranexamic acid works on the plasminogen/plasmin pathway — the keratinocyte-to-melanocyte activation signal — while Alpha Arbutin inhibits tyrosinase and Niacinamide blocks melanosome transfer. These are three distinct mechanisms covering three different steps. Combining them addresses more of the melasma pathway than any individual ingredient can cover alone.

Quick Tips

• Look for 2–5% concentration when choosing a topical tranexamic acid product — below this range, clinical evidence for meaningful results doesn't exist
• Combine with a tyrosinase inhibitor — tranexamic acid and Alpha Arbutin or TYROSTAT-09 address different parts of the melasma pathway and work better together than either alone
• Give it 8–12 weeks — clinical trials show meaningful MASI reduction at 8 weeks, with maximum results closer to 12 weeks
• For severe or persistent melasma, discuss oral tranexamic acid with a dermatologist — the oral route showed 58–65% MASI reduction and doesn't carry the skin irritation risk of topical formulations
• Always pair with SPF 50+ — tranexamic acid reduces melanocyte activation signals, but UV exposure continuously re-generates those signals